|
**Overview**: Hemoglobin A1c Panel**Introduction**: The Hemoglobin A1c Panel is a diagnostic tool designed to assess long-term glucose control using whole blood samples. In India, diabetes affects ~77 million adults (~11 percent prevalence), with HbA1c as the gold standard for diagnosis (≥6.5 percent) and monitoring (target <7 percent), reflecting average glucose over 2-3 months. High morbidity from under-testing in rural/low-SES patients, limited labs, delayed lifestyle/metformin leading to complications (retinopathy, nephropathy, CVD). Per endocrinology practices aligned with ICMR and RSSDI guidelines, the test employs spectrophotometry for HbA1c and average glucose over 1-2 days with high accuracy, valuable for diabetes screening and control assessment. This diagnostic falls under glucose monitoring and targets patients with diabetes risk or known diabetes, addressing accurate detection to guide therapy intensification. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise long-term glucose evaluation and reducing complications. Its whole blood-based approach ensures reliable measurement.**Other Names**: HbA1c Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/hematology, compliant with 2025 standards.**Historical Milestone**: HbA1c standard; in India, used in NPCDCS programs.**Purpose**: The test assesses 2 parameters including HbA1c to guide long-term glucose control evaluation, detect diabetes/prediabetes, inform therapy.**Test Parameters**: 1. HbA1c, 2. Average Glucose.**Pretest Condition**: Fasting 10-12 hours recommended; patients should report risk factors or diabetes.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for analysis).**Medical History**: Patients should provide details on diabetes duration, treatment, symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of poor control including complications, benefits of monitoring, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or hemoglobinopathies can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated HbA1c indicates poor control, necessitating specialist input. Normal may require follow-up in high-risk.**Specialist Consultation**: Diabetologists should be consulted for management.**Additional Supporting Tests**: Fasting/postprandial glucose for confirmation.**Test Limitations**: Affected by anemia/hemoglobin variants; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Diabetes Studies India 2023. |
